NASDAQ · ZURA
Zura Bio Limited
$3.85-$0.50 (-11.49%)
Zura Bio Limited’s quoted price sits in the lower half of its reported 52-week range, 48.25% below the high.
Loading market information…
XETRA · HPHA.DE · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Heidelberg Pharma AG’s quoted price sits in the lower half of its reported 52-week range, 35.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Heidelberg Pharma AG’s next earnings report is currently expected on Feb 3, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Heidelberg Pharma AG’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.85-$0.50 (-11.49%)
Zura Bio Limited’s quoted price sits in the lower half of its reported 52-week range, 48.25% below the high.
€5.35+€0.10 (+1.9%)
Mediclin AG’s quoted price sits in the upper half of its reported 52-week range, 7.76% below the high.
SEK 2.03+SEK 0.08 (+3.89%)
H100 Group AB: Technology · Software - Application.
€525.00+€5.00 (+0.96%)
LIMES Schlosskliniken AG’s quoted price sits in the upper half of its reported 52-week range, 11.76% below the high.
CA$0.70+CA$0.01 (+1.45%)
Healwell AI Inc.’s quoted price sits in the lower half of its reported 52-week range, 53.64% below the high.
€28.40+€0.20 (+0.71%)
MPH Health Care AG’s quoted price sits in the upper half of its reported 52-week range, 4.38% below the high.
£5.30£0.00 (0.0%)
4basebio PLC’s quoted price sits in the lower half of its reported 52-week range, 35.37% below the high.
€11.00€0.00 (0.0%)
Apontis Pharma AG’s quoted price sits in the lower half of its reported 52-week range, 10.93% below the high.
